Results 41 to 50 of about 7,000 (133)

Valacyclovir for the prevention of cytomegalovirus infection after kidney transplantation

open access: yesBMC Infectious Diseases
Background Cytomegalovirus (CMV) infection is a frequent complication after kidney transplantation (KT) and has various effects on recipient and graft survival.
Jin Sug Kim   +26 more
doaj   +1 more source

Chronic Ulcer on the Vulva

open access: yes
JEADV Clinical Practice, EarlyView.
Farhanaz Panjshiri   +2 more
wiley   +1 more source

Changing trends in prenatal screening and treatment of cytomegalovirus infection in France: 7‐year national cohort study (2017–2023)

open access: yesUltrasound in Obstetrics &Gynecology, Volume 67, Issue 6, Page 756-763, June 2026.
ABSTRACT Objectives Cytomegalovirus (CMV) is the leading cause of congenital infectious neurosensory impairment. We aimed to present national epidemiological data on maternal CMV infection during pregnancy in France, focusing in particular on primary infection in the periconceptional period or first trimester, and to assess the impact of changes in ...
P. Coste‐Mazeau   +176 more
wiley   +1 more source

Clinical and economic impact of universal screening for cytomegalovirus infection among pregnant women in Italy

open access: yesUltrasound in Obstetrics &Gynecology, Volume 67, Issue 6, Page 764-773, June 2026.
ABSTRACT Objective To evaluate the clinical and economic impact of universal screening for cytomegalovirus (CMV) in pregnant women in Italy, with valacyclovir (VCV) therapy in the case of maternal primary CMV infection, compared with no screening. Methods We developed a decision‐analytic model using a deterministic decision tree and compared the no ...
S. Ornaghi   +5 more
wiley   +1 more source

Retinal Zones Used as a Treatment Strategy in Management of Acute Retinal Necrosis and the Lessons Learnt: A Retrospective Study

open access: yesTNOA Journal of Ophthalmic Science and Research
Purpose: To use retinal zones and clock hours of involvement to plan treatment of acute retinal necrosis (ARN) during the induction phase. Design: Retrospective study.
Jonathan Malcolm Chavan   +4 more
doaj   +1 more source

Histomorphological Changes in the Fetal Rat Liver Following Exposure to Valacyclo-vir [PDF]

open access: yesIranian South Medical Journal
Background: Herpesviruses, a family of DNA viruses, cause various infections in humans and animals, affecting the skin and internal organs. Valacyclovir, a prodrug of acyclovir, is an effective antiviral drug widely used to treat diseases caused by ...
Mansureh Daneshfard   +4 more
doaj  

Synthesis and biological evaluation of novel urea and thiourea derivatives of valacyclovir [PDF]

open access: yesJournal of the Serbian Chemical Society, 2014
A series of novel urea and thiourea derivatives of valacyclovir were efficiently synthesized in high yields and evaluated their antiviral activity.
Katla Ramana Venkata   +4 more
doaj   +1 more source

Immune Modulation Related to High-Dose Valacyclovir Administration for Primary Cytomegalovirus Infection in Pregnancy: An Insight into Virus Behavior and Maternal Serology

open access: yesViruses
Cytomegalovirus (CMV) infection during pregnancy poses significant maternal and fetal health risks. Valacyclovir, an antiviral drug, has been explored as a therapeutic option for managing primary CMV infections in pregnant women.
Marco De Santis   +7 more
doaj   +1 more source

Clinical Features of Varicella-Zoster Virus Infection

open access: yesViruses, 2018
Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia.
Peter G. E. Kennedy, Anne A. Gershon
doaj   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

open access: yesAmerican Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy